TIMOTHY CRIPE

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression
    Andrew W Browne
    Division of Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States of America
    PLoS ONE 6:e19530. 2011
  2. pmc Ewing sarcoma: an eponym window to history
    Timothy P Cripe
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, ML7015, OH 45229, USA
    Sarcoma 2011:457532. 2011
  3. pmc VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
    F K Eshun
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Gene Ther 17:922-9. 2010
  4. ncbi request reprint Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress
    Balveen Kaur
    Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio, USA
    Curr Pharm Biotechnol 13:1842-51. 2012
  5. pmc Can less really be more? Using lessons from leukemia and cancer stem cells to make sense of oral maintenance for metastatic sarcoma
    Timothy P Cripe
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 50:737-8. 2008
  6. ncbi request reprint Promoting translational research in academic health centers: navigating the "roadmap"
    Timothy P Cripe
    Division of Hematology Oncology, MLC R7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Acad Med 80:1012-8. 2005
  7. pmc Targeting cancer-initiating cells with oncolytic viruses
    Timothy P Cripe
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA
    Mol Ther 17:1677-82. 2009
  8. doi request reprint Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein
    Xiaoyang Qi
    Division and Program in HumanGenetics, 3333 Burnet Avenue, Cincinnati, Ohio 45229 3039, USA
    Clin Cancer Res 15:5840-51. 2009
  9. ncbi request reprint Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferences
    Mark J Halsted
    Department of Radiology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
    AJR Am J Roentgenol 182:307-9. 2004
  10. pmc Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
    Gunnar Johansson
    Division of Experimental Hematology, University of Cincinnati, Cincinnati, OH, USA
    Mol Cancer Ther 7:1237-45. 2008

Collaborators

  • Thomas F Boat
  • Xiaoyang Qi
  • Ruty Mehrian Shai
  • Kathryn A Wikenheiser-Brokamp
  • J Khan
  • E Antonio Chiocca
  • David A Williams
  • Mark J Halsted
  • Heidi A Lane
  • Yonatan Y Mahller
  • Mark A Currier
  • Margaret H Collins
  • David S Dickens
  • Nancy Ratner
  • Timothy M Crombleholme
  • Balveen Kaur
  • Andrew W Browne
  • Arturo R Maldonado
  • F K Eshun
  • Chunyan Liu
  • Jon P Williams
  • Trisha M Wise-Draper
  • Mi Ok Kim
  • Jose A Cancelas
  • Yoshinaga Saeki
  • William H Baird
  • Gunnar Johansson
  • Sachin S Vaikunth
  • Maria C Ripberger
  • Lisa C Adams
  • Nehal S Parikh
  • Rafal Kozielski
  • Neeti S Bharatan
  • Chong H Ahn
  • Jason S Frischer
  • Jennifer L Leddon
  • R A Gillespie
  • Anil G Jegga
  • Bruce J Aronow
  • Chuck Klanke
  • W H Baird
  • J L Fitzpatrick
  • M A Currier
  • Bryan Mitton
  • Teresa A Morris
  • Rachael A Mintz-Cole
  • Susanne I Wells
  • Jonathan Grossheim
  • David S Simpson
  • Gerard C Grosveld
  • Sara C Kozma
  • Hirokazu Kambara
  • Takahiro Nobukuni
  • Nancy M Sawtell
  • John Perentesis
  • Rebecca A Gillespie
  • Greg Stroup
  • George Thomas
  • Ya Hsuan Hsu
  • Shyra J Miller
  • Ruty Mehrian-Shai
  • Fatima Rangwala
  • Betsy Di Pasquale
  • Patrick J Leavey
  • Charles Timmons
  • Anne Forus

Detail Information

Publications24

  1. pmc Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression
    Andrew W Browne
    Division of Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States of America
    PLoS ONE 6:e19530. 2011
    ..Refining this approach will usher a new era for clinical cancer screening that may be implemented in the developed and undeveloped world...
  2. pmc Ewing sarcoma: an eponym window to history
    Timothy P Cripe
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, ML7015, OH 45229, USA
    Sarcoma 2011:457532. 2011
    ..His vision of comprehensive cancer centers still drives our research infrastructure. Since his initial report, these organizations have helped us achieve numerous milestones in understanding and treating patients with Ewing sarcoma...
  3. pmc VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
    F K Eshun
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Gene Ther 17:922-9. 2010
    ..Our data suggest that i.v. oHSV can treat distant sites of disease and can be enhanced by antiangiogenic therapy, but only when given in the proper sequence...
  4. ncbi request reprint Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress
    Balveen Kaur
    Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center and The Ohio State University Medical Center, Columbus, Ohio, USA
    Curr Pharm Biotechnol 13:1842-51. 2012
    ..We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy...
  5. pmc Can less really be more? Using lessons from leukemia and cancer stem cells to make sense of oral maintenance for metastatic sarcoma
    Timothy P Cripe
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 50:737-8. 2008
  6. ncbi request reprint Promoting translational research in academic health centers: navigating the "roadmap"
    Timothy P Cripe
    Division of Hematology Oncology, MLC R7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Acad Med 80:1012-8. 2005
    ..The broad success of this program suggests that it might serve as a model for other academic health centers in promoting and conducting translational research...
  7. pmc Targeting cancer-initiating cells with oncolytic viruses
    Timothy P Cripe
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA
    Mol Ther 17:1677-82. 2009
    ..Here we review the available data regarding the ability of several different oncolytic virus types to target CICs for destruction...
  8. doi request reprint Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein
    Xiaoyang Qi
    Division and Program in HumanGenetics, 3333 Burnet Avenue, Cincinnati, Ohio 45229 3039, USA
    Clin Cancer Res 15:5840-51. 2009
    ..We investigated the antitumor efficacy and systemic biodistribution of nanovesicles comprised of saposin C coupled with dioleoylphosphatidylserine in preclinical cancer models...
  9. ncbi request reprint Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferences
    Mark J Halsted
    Department of Radiology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
    AJR Am J Roentgenol 182:307-9. 2004
    ..We describe a simple method for creating teaching cases from clinical data, radiologic images, surgical images, and images from pathologic slides that are presented at tumor board conferences...
  10. pmc Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
    Gunnar Johansson
    Division of Experimental Hematology, University of Cincinnati, Cincinnati, OH, USA
    Mol Cancer Ther 7:1237-45. 2008
    ..The preclinical tests described allow rapid screening strata for drugs that block MPNST growth, prior to tests in more complex models, and should be useful to identify drugs that synergize with RAD001...
  11. pmc Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus
    Yonatan Y Mahller
    Division of Hematology and Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States of America
    PLoS ONE 4:e4235. 2009
    ..Based on cues from normal stem cells, evidence for tumor populating progenitor cells has been found in a variety of cancers...
  12. doi request reprint Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors
    Arturo R Maldonado
    Division of Pediatric General and Thoracic Surgery, The Center for Molecular Fetal Therapy, Children s Hospital Medical Center, Cincinnati, OH, USA
    J Gene Med 12:613-23. 2010
    ..In the present study, we sought to leverage its selective expression to develop a novel oncolytic herpes simplex virus (oHSV) capable of targeting developmentally primitive cancers that express MDK...
  13. ncbi request reprint Cyclooxygenase-2 expression in pediatric sarcomas
    David S Dickens
    Department of Pediatrics, Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Pediatr Dev Pathol 5:356-64. 2002
    ..We conclude that the majority of these pediatric sarcoma samples express COX-2 to varying degrees. Therefore, studies testing the efficacy of COX-2 inhibitors in the treatment of pediatric sarcomas are warranted...
  14. pmc Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors
    Yonatan Y Mahller
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Cancer Res 68:1170-9. 2008
    ..These findings support the further development of combined TIMP-3 and oncolytic virotherapy for cancer...
  15. ncbi request reprint Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses
    Neeti S Bharatan
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    J Pediatr Hematol Oncol 24:447-53. 2002
    ..The authors sought to determine if pediatric sarcoma cells are also sensitive to HSV-mediated oncolysis...
  16. ncbi request reprint Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma
    David S Dickens
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Hematol Oncol 25:282-5. 2003
    ..COX-2 overexpression correlates with more aggressive disease in a variety of adult solid tumors...
  17. ncbi request reprint Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts
    David S Dickens
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, Ohio 45229, USA
    J Pediatr Hematol Oncol 25:709-14. 2003
    ..Because MMP inhibitor therapy induces COX-2 expression, the authors hypothesized that the combination of COX-2 and MMP inhibitors results in a synergistic antitumor effect...
  18. pmc Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences
    Chunyan Liu
    Division of Biostatistics and Epidemiology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Mol Ther 18:1724-30. 2010
    ..We recommend resampling as a method that readily adjusts the post hoc testing to be limited to only interesting comparisons and thereby avoids unduly sacrificing the power...
  19. ncbi request reprint Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models
    Nehal S Parikh
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 44:469-78. 2005
    ..High-risk neuroblastoma (Nb) is incurable using current treatment regimens in the majority of patients. Oncolytic virotherapy is a novel approach being tested for several types of adult cancers...
  20. ncbi request reprint Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses
    Mark A Currier
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Cancer Gene Ther 12:407-16. 2005
    ..Therefore, strategies to maximize intratumoral virus distribution at initial delivery should be sought...
  21. ncbi request reprint Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants
    Yonatan Y Mahller
    Division of Hematology Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 46:745-54. 2006
    ..Because NF-1-associated MPNSTs possess inherent hyperactive Ras, we hypothesized these tumors would be ideal therapeutic targets for oHSVs...
  22. pmc Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo
    Trisha M Wise-Draper
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Cancer Res 69:1792-9. 2009
    ..Taken together, our data uncover oncogenic DEK activities as postulated from its frequent up-regulation in human malignancies, and suggest that the targeted suppression of DEK may become a strategic approach to the treatment of cancer...
  23. ncbi request reprint Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model
    Yonatan Y Mahller
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Mol Ther 15:279-86. 2007
    ..Overall, oHSVs showed highly potent antitumor effects against MPNST xenografts, an effect not diminished by EGFR inhibition. Our data suggest that inclusion of MPNSTs in clinical trials of oHSV is warranted...
  24. pmc Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide
    Mark A Currier
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Mol Ther 16:879-85. 2008
    ..HSV replication was not detected in reactivation studies of isolated organs. Our findings suggest rRp450/CPA is safe and warrants further study as a potential combination in anticancer therapeutics...

Research Grants7

  1. Oncolytic HSV Therapy in Immunocompetent Sarcoma Models
    TIMOTHY CRIPE; Fiscal Year: 2006
    ..Our results will guide the design of future clinical trials using these novel agents. ..
  2. Oncolytic HSV Therapy in Immunocompetent Sarcoma Models
    TIMOTHY CRIPE; Fiscal Year: 2007
    ..Our results will guide the design of future clinical trials using these novel agents. ..
  3. Oncolytic HSV Therapy in Immunocompetent Sarcoma Models
    TIMOTHY CRIPE; Fiscal Year: 2009
    ..Our results will guide the design of future clinical trials using these novel agents. ..
  4. Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006
    Timothy P Cripe; Fiscal Year: 2010
    ..Because nonclinical data suggest systemic delivery of the virus may also have therapeutic benefit for metastases, this study may also enable future trials of systemic HSV1716. ..
  5. Oncolytic HSV Therapy in Immunocompetent Sarcoma Models
    Timothy P Cripe; Fiscal Year: 2010
    ..Our results will guide the design of future clinical trials using these novel agents. ..